Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
NIMA-related kinase 7, Nek7, is an important part of the activation of NLRP3 inflammatory bodies. Nek7 is widely present in eukaryotic cells and is one of the smallest members found in the NEK family. Nek7, located at both levels of the spindle, consists almost entirely of catalytic kinase domains with two amino-terminal kinase regions and no carboxy terminus. Nek6 and Nek7 have the same catalytic domain of 85%. The mitotic regulatory factor Polo-like kinase 1 (Plk1) and cyclin dependent kinase 1 (CDK1) activate Nek9, making it directly Combine Nek6 and Nek7 to control cytokinesis.
On the other hand, Nek7 is involved in the activation of NLRP3 inflammatory bodies as part of the NLRP3 inflammatory complex. Inactive NLRP3 inflammatory bodies are induced by the NF-κB pathway, and under the coordination of ROS pathway, K+ efflux, lysosomal disruption and Nek7, the inactive NLRP3 inflammatory body aggregates and activates, eventually leading to IL -1β, IL-18 maturation and secretion. By blocking the secretion of IL1β, IL-18 and binding to its receptor, it is possible to control and alleviate the progression of inflammatory diseases. Therefore, Nek7 may become a new target for the treatment of various inflammatory diseases.
Figure 1. Nek7 interacts and stabilizes TRF1 at telomeres upon oxidative damage. (Tan, R., et al. 2017)
Nek7 and Mitosis
Located in the centrosome, Nek7 is one of the 11 NEK kinases found in vertebrates and is one of the smallest members of the conserved non-mitosis Aspergillus (NIMA)-related family members. It is widely expressed in various tissues such as brain, heart, lung, liver, spleen and kidney. As a multi-functional protein kinase, Nek7 regulates proteins involved in biological processes. It is a highly conserved serine/threonine kinase (Nek) essential for mammalian survival, cellular changes, and mitosis. The role of the mitotic kinase Nek in cell mitosis is similar to that of NIMA. The regulation of key members of the N2 family members involved in G2/M phase during mitosis promotes centrosome maturation and affects chromatin concentration and spindle formation.
Nek7 Involved in the Activation of NLRP3 Inflammatory Bodies
Under normal growth conditions, Nek7 is in a low activity state, which is the key to maintaining the stability of the internal environment. However, in the pathological state, the homeostasis is destroyed, Nek7 is overexpressed, and multinucleated cells and apoptotic cells closely related to inflammation are produced in large quantities, eventually leading to the occurrence of inflammatory reactions in the body. Studies have shown that Nek7 is an important regulatory substance required for the activation of NLRP3 inflammatory bodies. In the downstream reaction of NLRP3 activation, Nek7 binds to the leucine rich repeat (LRR) in NLRP3 in an independent kinase manner, thereby further mediating the activation of NLRP3 inflammatory bodies, which cause an inflammatory response. Experiments have shown that Nek7 has a key function of reducing the dynamic stability of microtubules during the in vitro interval and phosphorylation of α-tubulin and β-tubulin, with microtubule acetylation and NLRP3 inflammatory body signaling. In the same way, in the cells knocked out of Nek7, alpha-tubulin acetylation increased, indicating that Nek7 is involved in microtubule acetylation during activation of NLRP3 inflammatory bodies.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.